摘要
骨髓增生异常综合征(MDS)是起源于造血干细胞的一组异质性髓系克隆性疾病,病理学表现为髓系细胞分化及发育异常,临床表现为无效造血、难治性血细胞减少、造血功能衰竭,高风险向急性髓系白血病(AML)转化。MDS治疗主要集中于两类问题:骨髓衰竭及并发症、AML转化。对于不同的患者而言,MDS患者自然病程和预后的差异性很大,治疗宜个体化。
Myelodysplastic syndrome （ MDS） is a group heterogeneous of clonal myeloid disorders derived from hematopoietic stem cells . The pathological manifestations are abnormalities of myeloid cell differentiation and development .The clinical manifestations are ineffective hematopoiesis, refractory cytopenia, hematopoiesis failure and high-risk conversion to acute myeloid leukemia （AML）.The treatment of MDS mainly focuses on two points： bone marrow failure and complications as well as AML transformation .For different patients , the natural disease course and prognosis of MDS varies widely and the treatment should be individualized .
出处
《中国妇幼健康研究》
2016年第11期1414-1415,共2页
Chinese Journal of Woman and Child Health Research
基金
国家自然科学基金资助项目(编号:81402133)
